Phaseline

Targets › IRAK4

IRAK4 (Interleukin-1 receptor-associated kinase 4): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. (UniProt, Q9NWZ3)

Open in Phaseline: the race on IRAK4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hangzhou Polymed BiopharmaceuticalsHPB-092
FLT3 and IRAK4 inhibitor
FLT3, IRAK4Phase 1Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Jun 2027
AstraZenecaAZD2962
IRAK4 inhibitor
IRAK4Phase 1Haematologic NeoplasmsOct 2028

Conditions

Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) (1) Haematologic Neoplasms (1)

Modalities

small molecule (2)

Companies

Hangzhou Polymed Biopharmaceuticals (1) AstraZeneca (1)

Related targets

FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.